Pancreatic Cancer Research

ResearcherCatharina ZiekenhuisActive in the last 2 years

Casper H.J. van Eijck

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-9511-2157; OpenAlex author ID A5006641161, A5103834169. Sources: ClinicalTrials.gov.

Their work

Papers
183 (first author 5, last author 44)
Trials
2 (principal investigator on 1)
Grants
0
Labs led
2
Collaborators
408
Papers, trials and grants by year

2011: 4 papers · 2012: none · 2013: none · 2014: 7 papers, 1 trial · 2015: 4 papers · 2016: 6 papers · 2017: 6 papers · 2018: 5 papers · 2019: 11 papers · 2020: 15 papers · 2021: 20 papers · 2022: 25 papers · 2023: 23 papers · 2024: 24 papers, 1 trial · 2025: 16 papers · 2026: 17 papers

Papers 50 of 183

  1. Transcriptome-Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant T… Co-author DOI 10.1002/ijc.70519↗
  2. The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life. Co-author DOI 10.1007/s00520-026-10568-3↗
  3. Bulk RNA sequencing deconvolution of early-onset pancreatic ductal adenocarcinoma identifies cancer-associated fibroblast subsets associated with survival and … Co-author DOI 10.1016/j.ctarc.2026.101490↗
  4. The impact of lower household income and distance to hospital on treatment and survival in patients with localized pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.116956↗
  5. Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. Co-author DOI 10.1016/j.ejso.2025.111165↗
  6. Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies. Co-author DOI 10.1016/j.hpb.2025.12.001↗
  7. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  8. The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer - Authors' reply. Co-author DOI 10.1016/s1470-2045(25)00729-6↗
  9. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  10. Gastrointestinal symptoms and health-related quality of life before and after pancreatectomy for pancreatic cancer (GO-PANC): longitudinal nationwide study. Co-author DOI 10.1093/bjs/znag122↗
  11. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  12. Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers. Co-author DOI 10.1093/oncolo/oyag373↗
  13. Staging Laparoscopy After Neoadjuvant Treatment for Pancreatic Cancer to Prevent Non-Therapeutic Laparotomy: Analysis in the PREOPANC-2 Randomized Trial. Co-author DOI 10.1097/sla.0000000000007025↗
  14. Pancreatic Ductal Adenocarcinoma with Atypical Genomic Profile: A Case of Long-Term Survival with KRAS-Wildtype, Microsatellite Instability and High Tumor Muta… Last author DOI 10.1159/000552404↗
  15. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  16. The Value of Stereotactic Radiotherapy After FOLFIRINOX in Patients with Pancreatic Cancer with Vascular Contact-A Nationwide, Retrospective Cohort Study. Last author DOI 10.3390/cancers18040700↗
  17. CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting. Co-author DOI 10.3390/cancers18111743↗
  18. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  19. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  20. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  21. Clinical relevance of next-generation sequencing in patients aged 60 years or younger with pancreatic cancer: A Nationwide prospective cohort study. Last author DOI 10.1016/j.ejca.2025.116065↗
  22. Immunogenicity and safety of COVID-19 vaccines in patients with pancreatic cancer. Co-author DOI 10.1016/j.hpb.2025.02.002↗
  23. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  24. REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer. Last author DOI 10.1038/s41467-025-66092-1↗
  25. Stroma and lymphocytes identified by deep learning are independent predictors for survival in pancreatic cancer. Co-author DOI 10.1038/s41598-025-94362-x↗
  26. Quality of Life in Patients with Locally Advanced Pancreatic Cancer During Stereotactic Radiotherapy Combined with Heat-Killed Mycobacterium Obuense Vaccinatio… Last author DOI 10.1089/jpm.2024.0160↗
  27. Resectability stages of pancreatic cancer: nationwide reference. Co-author DOI 10.1093/bjs/znaf120↗
  28. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  29. Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196↗
  30. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  31. Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. Co-author DOI 10.1097/sla.0000000000006910↗
  32. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  33. Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study. Co-author DOI 10.6004/jnccn.2024.7091↗
  34. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.7872↗
  35. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  36. FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination therapies and early response prediction. Co-author DOI 10.1016/j.ejca.2023.113440↗
  37. Gender differences in tumor characteristics, treatment allocation and survival in stage I-III pancreatic cancer: a nationwide study. Co-author DOI 10.1016/j.ejca.2024.114117↗
  38. A liquid biomarker signature of inflammatory proteins accurately predicts early pancreatic cancer progression during FOLFIRINOX chemotherapy. Last author DOI 10.1016/j.neo.2024.100975↗
  39. Overexpression of the adhesion signaling pathway is linked to short-term survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.11.001↗
  40. The tumor immune microenvironment in resected treatment-naive pancreatic cancer patients with long-term survival. Last author DOI 10.1016/j.pan.2024.08.014↗
  41. Preoperative chemoradiotherapy but not chemotherapy is associated with reduced risk of postoperative pancreatic fistula after pancreatoduodenectomy for pancrea… Last author DOI 10.1016/j.surg.2024.01.029↗
  42. GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoing upfront surgery. Co-author DOI 10.1016/j.xcrm.2024.101557↗
  43. Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1038/s41575-023-00856-2↗
  44. Tumor organoids improve mutation detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-024-75888-y↗
  45. Chemotherapy switch for localized pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.1093/bjs/znae244↗
  46. Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study. Co-author DOI 10.1093/jnci/djae070↗
  47. Minimum and Optimal CA19-9 Response After Two Months Induction Chemotherapy in Patients With Locally Advanced Pancreatic Cancer: A Nationwide Multicenter Study. Co-author DOI 10.1097/sla.0000000000006021↗
  48. Poor Prognostic Factors in Long-Term Survivors of Resected Pancreatic Ductal Adenocarcinoma: An International, Multicenter Cohort Study. Co-author DOI 10.1097/sla.0000000000006539↗
  49. HLA-A*02:01allele is associated with decreased risk and a longer survival in pancreatic cancer: Results from an exhaustive analysis of theHLAvariation in PDAC Co-author DOI 10.1101/2024.08.29.24312704↗
  50. Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer. Last author DOI 10.1136/gutjnl-2023-330480↗

Trials 2

  1. Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Th… Study chair NCT05927142↗
  2. Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer. Principal investigator NCT02292745↗

Closest collaborators

The 25 strongest of 408 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bas Groot Koerkamp · 84 shared papers, 2016–2026 · strength 11.38
  2. Marc G. Besselink · 80 shared papers, 2014–2026 · strength 10.20
  3. Johanna W. Wilmink · 50 shared papers, 2018–2026 · strength 7.36
  4. Marjolein Y.V. Homs · 36 shared papers, 1 shared trial, 2019–2026 · strength 5.93
  5. Hjalmar C. van Santvoort · 44 shared papers, 2014–2026 · strength 5.86
  6. Ignace H. J. T. de Hingh · 44 shared papers, 2014–2026 · strength 5.53
  7. Izaak Quintus Molenaar · 38 shared papers, 2014–2026 · strength 4.73
  8. Bert A. Bonsing · 41 shared papers, 2014–2026 · strength 4.59
  9. Dana A. M. Mustafa · 26 shared papers, 2019–2024 · strength 4.43
  10. Judith de Vos‐Geelen · 28 shared papers, 2016–2026 · strength 4.14
  11. Geertjan van Tienhoven · 32 shared papers, 2011–2026 · strength 4.00
  12. Casper W.F. van Eijck · 14 shared papers, 2023–2026 · strength 3.12
  13. Hanneke W.M. van Laarhoven · 23 shared papers, 2018–2026 · strength 3.09
  14. Martijn W.J. Stommel · 20 shared papers, 2020–2026 · strength 2.97
  15. Gijs A. Patijn · 22 shared papers, 2016–2026 · strength 2.83
  16. Vincent Erwin de Meijer · 18 shared papers, 2020–2026 · strength 2.67
  17. Michail Doukas · 14 shared papers, 2021–2026 · strength 2.55
  18. Quisette P. Janssen · 16 shared papers, 2019–2026 · strength 2.34
  19. Jacob L. van Dam · 16 shared papers, 2018–2026 · strength 2.32
  20. Thomas F. Stoop · 13 shared papers, 2024–2026 · strength 2.32
  21. J. Sven D. Mieog · 18 shared papers, 2017–2026 · strength 2.31
  22. Sebastiaan Festen · 16 shared papers, 2016–2026 · strength 2.26
  23. Freek R. van ‘t Land · 12 shared papers, 2021–2026 · strength 2.19
  24. Lydia G. van der Geest · 17 shared papers, 2016–2026 · strength 2.19
  25. Geert Kazemier M · 15 shared papers, 2016–2026 · strength 2.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.